Diabetes treatment is constantly evolving, with new therapeutic options emerging to improve patient outcomes. Recent research have focused on GLP-1 and GIP receptor agonists, a category of drugs that mimic the actions of naturally occurring hormones involved in bloodglucose regulation. These novel agents demonstrate significant results in improving

In the ever-evolving landscape of diabetes management, a novel approach is emerging that focuses on precisely targeting glucose levels. This innovative strategy involves leveraging the power of two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP have shown promising results in con